BioSpace reporter Gail Dutton reports on Icosavax's computationally designed virus-like particle (VLP) vaccine platform as a potential fi...
Developing
Best-in-Class
Vaccines
Computationally Designed VLP Vaccines
By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs.
RSV Vaccine
Our first vaccine candidate, IVX-121, is being developed to protect older adults from respiratory syncytial virus (RSV) disease.
In the News
For Nature Biotechnology's annual survey, the list of companies represents some of the best science that was spun out from academic insti...
· Two-component virus-like particle (VLP) technology developed at the Institute for Protein Design exclusively licensed from the Universi...